Bolt Biotherapeutics (NASDAQ:BOLT) Receives Buy Rating from Jonestrading

Jonestrading reissued their buy rating on shares of Bolt Biotherapeutics (NASDAQ:BOLT) in a research note published on Wednesday, AnalystRatings.com reports. The brokerage currently has a $45.00 price objective on the stock.

Other equities analysts have also issued reports about the company. SVB Leerink cut their price target on Bolt Biotherapeutics from $35.00 to $33.00 and set an outperform rating for the company in a report on Wednesday, November 10th. Zacks Investment Research raised Bolt Biotherapeutics from a sell rating to a hold rating in a report on Monday, October 18th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of Buy and a consensus target price of $41.00.

Shares of NASDAQ BOLT opened at $9.10 on Wednesday. The stock has a fifty day simple moving average of $12.24 and a two-hundred day simple moving average of $14.37. Bolt Biotherapeutics has a 1-year low of $7.58 and a 1-year high of $43.07. The firm has a market cap of $339.29 million and a price-to-earnings ratio of -0.54. The company has a current ratio of 9.39, a quick ratio of 9.39 and a debt-to-equity ratio of 0.08.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its quarterly earnings results on Monday, November 8th. The company reported ($0.63) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.75) by $0.12. The company had revenue of $0.75 million during the quarter, compared to the consensus estimate of $1.50 million. Analysts forecast that Bolt Biotherapeutics will post -2.62 EPS for the current year.

Large investors have recently bought and sold shares of the stock. American International Group Inc. raised its position in Bolt Biotherapeutics by 92.7% during the third quarter. American International Group Inc. now owns 12,526 shares of the company’s stock valued at $158,000 after purchasing an additional 6,025 shares in the last quarter. Bank of New York Mellon Corp raised its position in Bolt Biotherapeutics by 51.4% during the third quarter. Bank of New York Mellon Corp now owns 70,594 shares of the company’s stock valued at $893,000 after purchasing an additional 23,975 shares in the last quarter. Suvretta Capital Management LLC raised its position in Bolt Biotherapeutics by 38.9% during the third quarter. Suvretta Capital Management LLC now owns 1,325,500 shares of the company’s stock valued at $16,768,000 after purchasing an additional 371,411 shares in the last quarter. Metropolitan Life Insurance Co NY purchased a new stake in Bolt Biotherapeutics during the third quarter valued at about $91,000. Finally, Millennium Management LLC raised its position in Bolt Biotherapeutics by 410.2% during the third quarter. Millennium Management LLC now owns 163,131 shares of the company’s stock valued at $2,064,000 after purchasing an additional 131,160 shares in the last quarter. 89.49% of the stock is owned by institutional investors.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage immuno-oncology company, engages in the discovery, development, and commercialization of pharmaceutical products. The company develops BDC-1001, a human epidermal growth factor receptor 2 (HER2) for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; and BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers.

Recommended Story: S&P/TSX Index

Analyst Recommendations for Bolt Biotherapeutics (NASDAQ:BOLT)

Receive News & Ratings for Bolt Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bolt Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.